Cargando…

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

INTRODUCTION: Patients with human immunodeficiency virus (HIV) infection have an increased risk of cardiovascular disease (CVD). While viral suppression with antiretroviral therapy decreases CVD risk overall, several studies have suggested that certain antiretrovirals, particularly certain protease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chow, Dominic, Shikuma, Cecilia, Ritchings, Corey, Guo, Muxing, Rosenblatt, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125135/ https://www.ncbi.nlm.nih.gov/pubmed/27677263 http://dx.doi.org/10.1007/s40121-016-0132-z

Ejemplares similares

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
por: LaFleur, Joanne, et al.
Publicado: (2017)

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens
por: Cure, Sandrine, et al.
Publicado: (2015)

Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Symptoms of Autonomic Dysfunction in Human Immunodeficiency Virus
por: Chow, Dominic, et al.
Publicado: (2015)

Two Cases of Multidrug-Resistant Human Immunodeficiency Virus Infection Treated with Atazanavir and Lopinavir/Ritonavir Combination Therapy
por: Choi, Heekyoung, et al.
Publicado: (2008)

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
por: Naidoo, Anushka, et al.
Publicado: (2017)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV
por: Li, Michael, et al.
Publicado: (2020)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Human immunodeficiency virus infection and cardiovascular risk
por: Zaharia-Kézdi, Erzsébet Iringó, et al.
Publicado: (2014)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

Human immunodeficiency virus & cardiovascular risk
por: Barbaro, Giuseppe, et al.
Publicado: (2011)

Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection
por: Pinto, Daniela Sofia Martins, et al.
Publicado: (2018)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)
por: Gallant, Joel, et al.
Publicado: (2017)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe
por: Ngara, Bernard, et al.
Publicado: (2021)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013)

Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones
por: Grant, Michael T., et al.
Publicado: (2017)

Atazanavir Crystal–Induced Chronic Granulomatous Interstitial Nephritis
por: Varghese, Vipin, et al.
Publicado: (2020)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy
por: Idiculla, Jyothi, et al.
Publicado: (2018)

Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2019)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Effects of Antiretroviral Therapy on Autonomic Function in Early HIV Infection: A Preliminary Report
por: Chow, Dominic, et al.
Publicado: (2012)

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review
por: Saint-Lary, Laura, et al.
Publicado: (2022)

Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population
por: Hasse, Barbara, et al.
Publicado: (2015)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Long-term treatment of patients with HIV-1: the role of atazanavir
por: Artacho, Miguel Ángel, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4qr2vbjibpjklhcnbeov3stcr1